Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
PaperCitations, authors & open-access status
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 599 citations, 2017 year and green oa status.
599
Citations
2017
Year
green
OA Status